Precision Medicine Company Aims to Make Prescriptions Personal
MINNEAPOLIS (October 26, 2017) – The Concierge Medicine Forum held this week in Atlanta will feature an expert on pharmacogenomics from OneOme, a leading precision medicine company. Ryan Gregg, Ph.D, medical science liaison from OneOme, will present a session on pharmacogenomics on Friday, October 27, at 11:05 a.m. at the Forsyth Conference Center in Cumming, Georgia. Pharmacogenomics is an emerging field that identifies how a patient’s unique DNA and current medications may affect their response to medications.
RELATED STORY | DPC
OFFICIAL POSITION, STATEMENT: Use and Application of Pharmacogenomics Inside Concierge Medicine and Direct Primary Care Clinics
OneOme’s RightMed® pharmacogenomic solution better enables providers to more effectively treat conditions in primary care and a variety of specialty areas, including mental health, cancer, heart disease, pain, and more. OneOme aims to make prescriptions personal and improve patient health by increasing drug effectiveness and helping patients avoid unintended interactions. OneOme’s RightMed test has been adopted by concierge medicine clinics and health systems throughout the world.
Ryan Gregg’s session is titled: “Pharmacogenomics – Insights from Real-World and Modeling Studies.” Ryan Gregg, Ph.D. He earned a Ph.D. in pharmacology from the Center for Substance Abuse and Research at Temple University School of Medicine. Gregg’s experience includes pre-clinical and clinical research in psychiatry, hematology, pain, and oncology. At OneOme, Gregg provides education and training to physicians, pharmacists, and nurse practitioners to implement pharmacogenomic testing into clinical practice.
RELATED STORY | FREE | AUDIO PODCAST
OneOme’s pharmacogenomic testing and clinical support tools are easy-to-use, intuitive, and ready to be integrated into clinical practices. OneOme’s RightMed comprehensive test covers hundreds of medications at an accessible price point. To date, over 450 locations from over 22 different countries have ordered OneOme’s RightMed test and OneOme continues to build research and commercial partnerships across the globe.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more, visit oneome.com.
OneOme Editor’s Note: Mayo Clinic has financial investment in the technology referenced in this news release. The revenue that Mayo Clinic will receive is used to support its not-for-profit mission in patient care, education and research.
Categories: DPC News